Prescribing Information
Contact Us
Patient Information
Adverse event information can be found at the bottom of the page
About Fetcroja
®
Coverage and Tolerability
Susceptibility Testing
Using Fetcroja
®
Ordering Fetcroja
®
Expert Perspectives
About Fetcroja®
>
WHO IS FETCROJA® FOR?
MECHANISM OF ACTION
MODE OF CELL ENTRY
HOW DOES THIS SUPPORT THE NICE RECOMMENDATION FOR USE OF FETCROJA<sup>®</sup> IN ENGLAND?
ADDITIONAL PROPERTIES
Coverage and Tolerability
>
ANTIMICROBIAL COVERAGE
HOW DOES THIS SUPPORT THE NICE RECOMMENDATION FOR USE OF FETCROJA<sup>®</sup> IN ENGLAND?
TOLERABILITY
CLINICAL DATA
Sentry data
Susceptibility Testing
>
Commercially available susceptibility testing devices
Interpretative criteria and quality control ranges
FETCROJA® SUSCEPTIBILITY TESTING MATERIALS
Summary table of Fetcroja® susceptibility testing materials
HOW DOES THIS SUPPORT THE NICE RECOMMENDATION FOR USE OF FETCROJA<sup>®</sup> IN ENGLAND?
Using Fetcroja®
>
Dosage
SPECIAL POPULATIONS
RECONSTITUTION AND ADMINISTRATION
STORAGE
Ordering Fetcroja®
Expert Perspectives
>
Case study: Recurrent neurosurgical site infection
Case study: Treatment of a diabetic foot infection with bacteraemia
Pseudomonas Webinar
Antimicrobial resistance (AMR) and the role of cefiderocol
Experience with cefiderocol
Fetcroja (cefiderocol) as rescue therapy in (ICU) patients
Coverage and Tolerability
>
APEKS-NP Clinical Trial Animation
FETCROJA® APEKS-NP CLINICAL TRIAL ANIMATION
PP-UK-FDC-0868 | August 2023
You are now leaving the Fetcroja
®
website.
Do you wish to continue?
PP-UK-FDC-0821 | March 2023
No, Go Back
Yes, Continue
Stay Up To Date
